IFNB1 and myeloid sarcoma: In contrast, IFN-β therapy reduced the anti-env antibody reactivity for HERV-H and HERV-W [104] and, similarly, the MSRV load in the blood of MS patients decreased after one year of therapy with IFN-β [105].